FDA OKs Trastuzumab Deruxtecan for Earlier Use in Breast Cancer FDA OKs Trastuzumab Deruxtecan for Earlier Use in Breast Cancer

With a standard approval from the FDA, the HER2-directed antibody drug conjugate can now be used earlier in treatment to delay disease progression.FDA Approvals
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news